TXG — 10x Genomics, Inc.

Nasdaq · Unknown · Unknown · CIK 1770787 ·
Last close
$24.62
Market Cap
$2.88B
52W High
$26.44
52W Low
$15.90
ADV30
2,787,816
Next earnings
2026-08-06
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 150,843,000 106,178,000 -17,046,000 -13,470,000 1,015,759,000 490,285,000 201,435,000
Dec 2025 166,030,000 113,045,000 -19,541,000 -16,252,000 1,041,365,000 473,966,000 245,039,000
Sep 2025 149,002,000 100,307,000 -32,242,000 -27,472,000 1,027,361,000 432,508,000 242,241,000
Jun 2025 172,908,000 125,084,000 -10,574,000 34,538,000 979,970,000 397,712,000 206,691,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$127,819,000
Investing CF
$-12,856,000
Financing CF
$-2,036,000
CapEx
$-5,639,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.17
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,524,061,000
Inventory
$53,487,000
Receivables
$56,137,000
ST Investments
$49,563,000
EBIT TTM
$39,149,000
Pretax Income TTM
$-19,248,000
Interest Exp TTM
$3,000
Analysts
13

Yahoo Snapshot (yfinance, live)

Total Revenue
$638,782,976
EBITDA
$-30,669,000
Free Cash Flow
$124,545,128
Enterprise Value
$2,547,863,552
Total Cash
$539,848,000
Total Debt
$81,389,000
Shares Out
116,877,317
Trailing EPS
$-0.17
Book Value
$6.24
ROE
-3.0%
ROA
-4.5%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 642,823,000 -110,885,000 -43,544,000 1,041,365,000 245,039,000 136,050,000
Dec 2024 610,785,000 -194,559,000 -182,627,000 918,636,000 208,502,000 6,664,000
Dec 2023 618,727,000 -204,349,000 -255,099,000 965,143,000 224,100,000 -15,197,000
Dec 2022 516,409,000 -167,944,000 -166,000,000 1,028,980,000 223,237,000 -33,606,000

TTM Snapshot

Revenues TTM
$563,117,000
NetIncome TTM
$-189,968,000
OpCashFlow TTM
$0
Assets (Latest)
$918,636,000
Forward EPS
$0.20

News headlines (Yahoo Finance, 1h cache)

The 5 Most Interesting Analyst Questions From 10x Genomics’s Q1 Earnings Call
2026-05-18 17:00 · Yahoo
1 Cash-Producing Stock on Our Watchlist and 2 We Question
2026-05-13 21:40 · Yahoo
Is It Time To Reassess 10x Genomics (TXG) After Its Recent Share Price Surge?
2026-05-13 05:18 · Yahoo
Why 10x Genomics (TXG) Stock Is Down Today
2026-05-13 03:48 · Yahoo
United Natural Foods Stock Is Up 85%. One Investor Just Sold Out Completely
2026-05-12 17:23 · Yahoo
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year
2026-05-12 17:10 · Yahoo
This $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116%
2026-05-12 16:59 · Yahoo
A Look At 10x Genomics (TXG) Valuation After A Strong Year And Recent Share Price Pullback
2026-05-12 13:22 · Yahoo
TXG Q1 Deep Dive: Atara Launch, Spatial Platform Transition, and AI-Driven Demand
2026-05-11 23:56 · Yahoo
10x Genomics Q1 Earnings Call Highlights
2026-05-09 06:07 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.